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Fructosamine is a valuable marker 
for glycemic control and predicting 
adverse outcomes following total 
hip arthroplasty: a prospective 
multi‑institutional investigation
Noam Shohat1,2, Karan Goswami1, Leigham Breckenridge1, Michael B. Held3, 
Arthur L. Malkani4, Roshan P. Shah3, Ran Schwarzkopf5 & Javad Parvizi1*
Recently, fructosamine has shown promising results in predicting adverse outcomes following 
total knee arthroplasty. The purpose of this study was to assess the utility of fructosamine to 
predict adverse outcomes following total hip arthroplasty (THA). A prospective multi‑center study 
involving four institutions was conducted. All primary THA were evaluated for glycemic control 
using fructosamine levels prior to surgery. Adverse outcomes were assessed at a minimum 1 year 
from surgery. Primary outcome of interest was periprosthetic joint infection (PJI) based on the 
International Consensus Meeting (ICM) criteria. Secondary outcomes assessed were superficial 
infections, readmissions and death. Based on previous studies on the subject, fructosamine levels 
above 293 µmol/L were used to define inadequate glycemic control. Overall 1212 patients were 
enrolled in the present study and were available for follow up at a minimum 1 year from surgery. Of 
those, 54 patients (4.5%) had elevated fructosamine levels (> 293 µmol/L) and these patients were 
6.7 times more likely to develop PJI compared to patients with fructosamine levels below 293 µmol/L 
(p = 0.002). Patients with elevated fructosamine were also associated with more readmissions (16.7% 
vs. 4.4%, p < 0.007) and a higher mortality rate (3.7% vs. 0.6%, p = 0.057). These associations remained 
statistically significant in a multi‑regression analysis after adjusting for age, comorbidities and length 
of stay; Adjusted odds ratio were 6.37 (95% confidence interval 1.98–20.49, p = 0.002) for PJI and 2.68 
(95% confidence interval 1.14–6.29, p = 0.023) for readmissions. Fructosamine is a good predictor of 
adverse outcomes in patients undergoing THA and should be used routinely to mitigate morbidity and 
mortality risk.
Much attention has been devoted in recent years to develop strategies that can mitigate the risk of adverse out-
comes following total joint arthroplasty (TJA), with a special emphasis to strategies that can reduce periprosthetic 
joint infection (PJI)1,2. Among the risk factors known to affect outcome of any surgical procedure, including TJA, 
is proper glycemic  control1,3–5. The latter is ever more important as up to 50% of patients undergoing THA were 
found to have  hyperglycemia6,7. Moreover, glycemic control is considered one of the only modifiable factors, the 
control of which is demonstrated to reduce the risk of  complications8,9.
While it is well acknowledged that hyperglycemia is associated with adverse outcomes following surgery, 
there remains controversy about which glycemic markers to use and what interval from surgery they are most 
 predictive1,4. In the preoperative period, 3 month glycemic control as measured by glycated hemoglobin (HbA1c) 
has been used, whereas in the perioperative period fasting glucose is routinely used for risk  stratification10–13 
Many institutions now use predetermined cutoffs values for both fasting glucose and HbA1c, and postpone 
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surgery to patients with elevated levels of one or both of these glycemia markers. The effectiveness of this protocol 
in reducing complications is yet to be  proven14.
Fructosamine is not a new glycemic  marker15. The monitoring of glycated protein (mainly albumin) was intro-
duced 40 years ago and has recently been revisited as a tool for preoperative screening due to clear advantages 
in the preoperative  period16,17. The fact that fructosamine represents sugar levels over a 2–3 week period makes 
it a valuable marker for both screening and monitoring therapeutic interventions. If patients with inadequate 
glycemia control were to have elective surgery postponed based on elevated fructosamine levels, return to better 
glycemic control could be confirmed within 2 weeks using fructosamine as opposed to 3 months using HbA1c.
In a recent study, fructosamine was shown to be more valuable than HbA1c in predicting early complications 
following  TKA16. The purpose of this prospective multicenter study was to evaluate the role of fructosamine in 
predicting 1-year complications in patients undergoing elective THA.
Materials and methods
Following IRB approval by the ethics committee of Thomas Jefferson University Hospital (IRB-16D.225), NYU 
Langone (IRB-i18-00017), Columbia University (IRB-AAAR7050), and University of Louisville (IRB-17.0813), 
these four academic centers participated in this prospective study. Written informed consent was obtained from 
all participants of this study. All methods were carried out in accordance with the relevant guidelines and regu-
lations based on the approvals. During the time period between August 2017 and November 2018, all elective 
primary THA patients performed by 8 fellowship trained surgeons were investigated for glycemic control using 
fructosamine, HbA1c and fasting plasma glucose (FPG) levels within four weeks prior to surgery. Postoperative 
day 1 (POD) morning glucose levels were also captured. Patients were followed-up for a minimum of 1 year.
Data collection. Demographic and perioperative factors that could serve as confounders were collected and 
are presented in Table 1. Obesity was defined as body mass index (BMI) above 30 kg/m2. Charlson Comorbidity 
Index (CCI) was calculated for each patient based on medical records. Special attention was given to diabetic 
status and was collected both from self-reported questionnaires, as well as from medical records. Diabetes was 
considered complicated if systemic complications were present.
The primary outcome assessed was PJI based on the 2018 International Consensus Meeting (ICM)  definition18. 
Secondary adverse outcomes included superficial wound complications, hospital readmissions for causes related 
to their surgery (including deep vein thrombosis and prosthesis-related complications) and death. A wound 
complication was predefined and included more than 1 week of drainage, postponed hospital discharge due to 
wound issues, the use of antibiotics, or return to the operating room for wound care.
Statistical analysis. A power analysis was performed based on prior literature and the rate of PJI stratified 
based on fructosamine levels (above and below 293 µmol/L) was predicted to be approximately 1:3.5. Sample size 
was projected supposing a 2-sided t-test with an alpha level of 0.05 and 0.8 power. A sample size of 1100 patients 
was deemed appropriate. Inadequate glycemic control was assumed in patients with fructosamine levels above 
293 µmol/L (4) For verification, receiver operating characteristic (ROC) analysis was performed and the area 
under the curve (AUC) was calculated for fructosamine and the risk for PJI. Adverse outcomes were assessed 
following glycemic control stratification. Categorical variables were analyzed using the Chi square test and con-
tinuous variables by the Student’s t-test. A p value < 0.05 was considered significant except for death, where a p 
value < 0.1 was set to be considered statistically significant due to its gravid impact. All demographic, comorbid-
ity and hospitalization variables that were significantly different between those with high (above 293 µmol/L) 
and normal (below 293 µmol/L) fructosamine were included in a logistic regression analysis, and adjusted odds 
ratios were calculated. Death was not assessed in a regression analysis due to the minor incidence. A scatter plot 
was created to assess the association between fructosamine and HbA1c levels. A subgroup analysis of patients 
with FPG levels above 100 mg/dL was also performed to assess the utility of fructosamine in a more specific 
cohort.
Table 1.  Demographic characteristics and comorbidities of the entire cohort and differences between those 
with fructosamine levels below and above 293 µmol/L. Data are presented as mean values (SD) or as numbers 
(%). *Excluding diabetic element of scoring.
Overall Fructosamine < 293 µmol/L (n = 1158) Fructosamine ≥ 293 µmol/L (n = 54) p value
Age, year 63.97 (11.39) 63.68 (11.33) 70.12 (11.16)  < 0.001
Sex (female) 616 (50.8%) 594 (51.3%) 22 (40.7%) 0.163
Operated hip (right) 573 (48.1%) 547 (47.2%) 26 (48.1%) 0.797
Body-mass index (kg/m2) 29.07 (5.40) 29.10 (5.43) 28.32 (4.64) 0.305
Obese (> 30 kg/m2) 457 (38.4%) 437 (38.4%) 20 (37.7%) 1.000
Charlson Comorbidity Index 0.52 (1.00) 0.49 (0.94) 1.24 (1.60) 0.001
Score ≥ 3 63 (5.2%) 55 (4.75%) 8 (14.81%)  < 0.001
History of diabetes mellitus 111 (9.2%) 90 (7.8%) 21 (38.9%)  < 0.001
With complications 9 (7.4%) 5 (0.4%) 4 (7.4%)  < 0.001
Length of stay (days) 1.51 (1.40) 1.49 (1.40) 2.00 (1.44) 0.009
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Results
During the study period a total of 1,212 patients (616 females) underwent THA who had preoperative fruc-
tosamine collected and were available for 1-year follow-up after their primary THA. Mean age was 63.9 years 
(standard deviation [SD] 11.39). Overall, 111 patients (9.2%) were known to have diabetes. Screening all THA 
patients using HbA1c revealed that many patients were unaware of their diabetic state. Of the 303 patients who 
had HbA1c levels in the prediabetes range (5.7–6.5%) upon screening, only 45 (15%) were previously diagnosed 
with diabetes (i.e. 85% were unaware of their pre-diabetic state), and of the 88 patients with HbA1c levels in the 
diabetic range (≥ 6.5%), only 51 patients (58%) had a prior diagnosis of diabetes (i.e. 42% were unaware they 
had diabetes) (Fig. 1).
Mean fructosamine levels were 241.91 µmol/L (range, 108 to 490) for the entire cohort. In 54 patients (4.5%) 
fructosamine levels were greater than 293 µmol/L indicating inadequate glycemic control, however only 21 of 
them (38.9%) had a prior diagnosis of diabetes. Compared to patients with fructosamine levels below 293 µmol/L, 
patients with levels greater than 293 µmol/L were older (p < 0.001), had more comorbidities (p = 0.001) including 
diabetes (p < 0.001) and had a longer hospital stay (p = 0.009), as presented in Table 1.
High fructosamine levels were associated with PJI (AUC 0.58, 95% Confidence Interval 0.40–0.70]. Fructosa-
mine levels above 293 µmol/L were significantly associated with PJI, readmissions and death (Table 2, Fig. 2). PJI 
rates were 6.64 times higher (p = 0.002), readmission rates were 3.80 times higher (p = 0.001), and mortality was 
6.17 times higher (p = 0.057) in patients with elevated fructosamine levels. Superficial wound complication rates 
were similar between those with fructosamine levels above and below 293 µmol/L (3.7% versus 2.5%, p = 0.645). 
After adjusting for age, comorbidities and length of stay which were all significantly (p < 0.05) higher in those 
with fructosamine above 293 µmol/L, the above associations with PJI (adjusted odds ratio 6.37, 95% confidence 
interval 1.98–20.49; p = 0.002) and readmissions (adjusted odds ratio 2.68, 95% confidence interval 1.14–6.29; 
p = 0.023) remained statistically significant.
In the subgroup of patients with FPG above 100 mg/dL (n = 423), a higher proportion of patients had fruc-
tosamine levels above 293 µmol/L (7.6%). Four of the 5 PJI cases, 7 of the 9 readmissions and 1 of the 2 deaths 
that were captured in those with elevated fructosamine had occurred in patients with FPG above 100 mg/dL. 
Figure 1.  Proportion of patient with known diabetes with HgbA1c levels in the prediabetes and diabetes range.
Table 2.  Adverse outcomes in patients with high (≥ 293 µmol/L) and low (< 293 µmol/L) fructosamine levels 
in the entire cohort and in a subgroup who had glucose levels above 100 mg/dL. PJI periprosthetic joint 
infection.
Complications








(n = 391) p value
PJI 16 (1.4%) 5 (9.3%) 0.002 6 (1.5%) 4 (12.5%) 0.004
Wound complication 29 (2.5%) 2 (3.7%) 0.645 14 (3.6%) 2 (6.3%) 0.345
Readmission 51 (4.4%) 9 (16.7%) 0.001 16 (4.1%) 7 (21.9%) 0.001
Mortality 7 (0.6%) 2 (3.7%) 0.057 4 (1.0%) 1 (3.1%) 0.327
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As before, associations with PJI and readmissions were significantly higher in those with fructosamine levels 
above 293 µmol/L (Table 2).
There was a positive correlation between fructosamine and HbA1c levels (Fig. 3). Of the patients who had 
fructosamine levels greater than 293 µmol/L, 39 patients (72.2%) were in the prediabetes or diabetes range 
based on HbA1c levels. Fructosamine levels greater than 293 µmol/L were significantly associated with higher 
FPG, and higher POD-1 glucose levels (Table 3). However, among the 5 patients with fructosamine greater than 
Figure 2.  Complication rates stratified based on fructosamine levels below 293 μmol/L (n = 1158) and above 
293 μmol/L (n = 54). *Represents statistically significant differences.
Figure 3.  A scatter plot correlating HbA1c and fructosamine  (R2 = 0.18).
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293 µmol/L who developed PJI, only 2 had a diagnosis of diabetes. HbA1c levels were less than 7.5% in 2 of these 
patients (40%) and less than 8% in 4 of them (80%). On the contrary, there were no patients with HbA1c levels 
above 7.5% or 8.0% that did not have fructosamine levels above 293 µmol/L.
Discussion
The main finding of this prospective study was that fructosamine, as a glycemic marker, is an excellent predictor 
of adverse outcomes following THA. Another important, and sobering, finding of the study, that corroborates 
prior  studies6,7, is that a large proportion of patients undergoing elective THA appear to be hyperglycemic or 
undiagnosed diabetics who are unaware of their poor glycemic control. In a recent International Consensus 
Meeting (ICM), the issue of screening all patients for hyperglycemia prior to surgery was discussed with 76% 
of delegates voted in favor of such  protocol19. The rationale behind such recommendation is that by evaluating 
glycemic control only in patients with known diabetes, we are neglecting a large cohort of patients with unrec-
ognized hyperglycemia and/or diabetes that are at increased risk for  complications20. The major question that 
remains is which agent best represents the glycemic control of a patient.
HbA1c remains the gold standard for assessing glycemic control and is invaluable in the treatment of diabetic 
patients. It is a predictor of diabetic complications, and interventions that lower HbA1c levels have proved them-
selves useful in reducing the risk of  complications21. Whereas the overall utility of HbA1c is beyond question, 
discordances between HbA1c and other clinically reliable biochemical measures of glycemic control such as fruc-
tosamine are commonly  encountered22. These discordances are mainly attributed to the time frame over which 
HbA1c equilibrates compared with shorter-term measures of plasma  glucose23–25. It has also been hypothesized 
that discordances between HbA1c and other measures of glycemia such as fructosamnie are due to physiologic 
processes consistent within individuals over time and these variations by them self may have a role in predict-
ing  complications26. Our finding of elevated fructosamone levels in patients without a diagnosis of diabetes or 
elevated HbA1c levels is in accordance with the above mentioned discordances and reinforces recent findings 
in arthroplasty  patients16,17,27.
It has become common practice to evaluate the preoperative HbA1c level in patients with diabetes prior to 
surgery and postpone surgery in patients with elevated  levels19. The American Diabetes Association (ADA) states 
that HbA1c > 7% is representative of poor glycemic  control28. In a recent multicenter study on patients undergo-
ing TJA, HbA1c > 7.7% was found to be associated with higher rate of PJI and other  complications10. Based on the 
latter study, our institution and many others will cancel elective orthopedic surgery in patients with HbA1c > 7.5 
or 8%4,11,29. While the rationale behind such practice appears to be logical, the value of this protocol in reducing 
postoperative complications has not been proven. Further, HbA1c represents glycemic control over the 120 day 
life cycle of red blood cells. Thus, patients with elevated HbA1c who had their elective surgery cancelled may 
need to wait for 3 months before confirming that implementation of better glycemic control was effective and 
be able to undergo surgery. Another glycemic marker that has proven to be valuable is fasting blood  glucose4. 
The Center for Disease Control (CDC) in their recent guidelines for prevention of surgical site infection states 
that patients with fasting glucose of 200 mg/dL have a poor glycemic control and should not undergo elective 
surgical  procedures1. Though valuable, there are logistic issues associated with measuring fasting glucose levels 
in patients awaiting elective surgery. Further, fasting glucose levels are under immense influence of numerous 
factors including stress, which most patients undergoing surgery would  exhibit30,31.
Fructosamine is a measure of glycated protein in the plasma, with albumin being the major constituent, 
and thus reflects glycemic control over the proceeding 2–3 weeks32. In daily diabetes care unrelated to surgery, 
fructosamine adds little to the commonly used HbA1c, as majority of literature pertaining to screening and treat-
ment is on the latter. In the preoperative period, fructosamine has a substantial advantage as a glycemic marker 
as it allows one to monitor response to treatment in a much shorter time frame compared to HbA1c. The cur-
rent study adds to the body of literature that shows fructosamine is a valuable screening tool for hyperglycemia 
in patients undergoing elective  surgery16,17. There is a direct correlation between fructosamine and HbA1c in 
patients with and without diabetes, as seen in this study. While a correlation between the two glycemic markers 
exists, there are important differences, mostly related to the time frame of glycemic control that each of these 
markers represent. There are variations in institutional policies regarding the optimal threshold for HbA1c, with 
most institutions using HbA1c between 7.5 and 8.0% as representative of poor glycemic  control4. The current 
Table 3.  Data on glycemic control in patients with fructosamine levels below and above 293 µmol/L. Data are 
presented as mean values (SD) or as numbers (%). *Excluding diabetic element of scoring.
Glycemic control Overall
Fructosamine < 293 µmol/L 
(n = 1158)
Fructosamine ≥ 293 µmol/L 
(n = 54) p value
Hemoglobin A1c, % 6.15 (15.67) 6.12 (16.1) 6.71 (1.33) 0.788
5.7% to 6.5% (prediabetes) 303 (30.0%) 293 (30.6%) 10 (18.9%)  < 0.001
 ≥ 6.5% (diabetes) 88 (8.7%) 59 (6.2%) 29 (54.7%)  < 0.001
 ≥ 7.5% 30 (3.0%) 10 (1.0%) 20 (37.7%)  < 0.001
Preoperative fasting glucose (mg/
dL) 100.61 (24.39) 99.11(20.82) 133.88 (55.53)  < 0.001
 ≥ 100 (mg/dL) 423 (37.9%) 391 (36.6%) 32 (66.7%)  < 0.001
Postoperative day 1 glucose 137.51 (32.42) 135.32 (29.14) 171.67 (55.09)  < 0.001
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study demonstrates that if such thresholds for HbA1c were to be used, instead of the fructosamine levels, many 
patients who developed PJI or had adverse outcome would have been missed.
This study adds to recent reports on the utility of fructosamine as a valuable glycemic marker, particularly 
in patients undergoing elective  TJA16,17. The cost of fructosamine testing is negligible compared to the costs 
associated with complications following THA, and if it is indeed used in the preoperative period it may also be 
cos-beneficial. The cost of a single fructosamine test is $19.77 amounting to a total cost of $23,961 in the current 
study whereas the cost of treating a single PJI event is estimated as $100,000 per  case33. The fact that 5 patients 
with high fructosamine levels developed PJI that could have been theoretically prevented, support the notion 
that all patients undergoing THA should be screened for glycemic control using fructosamine. However, we are 
aware that screening all patients prior to surgery may not be possible for many institutions. In an attempt to 
isolate a smaller group that would benefit from screening, we performed a sub-analysis of the current cohort 
and discovered that patients with fasting glucose > 100 mg/dL would most benefit from glycemic screening using 
fructosamine. Screening only those with high fasting glucose would reduce by 65% the number of patients that 
are screened, and still capture 80% of the patients that are at higher risk of postoperative complications. Interest-
ingly, not only high fructosamine levels are informative, but normal levels are also beneficial in risk stratification. 
A normal fructosamine level in patients with FPG > 100 mg/dL can be reassuring for the treating physician as 
complication rates in this group were similar to those seen with FPG < 100 mg/dL. This strategy of screening 
may be an efficient compromise for certain centers.
While we cannot say for sure why exactly fructosamine is such a powerful prognostic marker, there are sev-
eral theories. First, fructosamine reflects fluctuations in glucose which have been associated with complications 
following  TJA27,34,35. Both in-vivo and in-vitro studies attribute the negative effects of these fluctuations to the 
activation of pro-inflammatory proteins and excessive oxidative  stress36. Furthermore, short-term fluctuations 
in glucose levels may have a larger effect on inflammatory cytokine levels than continuous hyperglycemia and 
has been shown to affect all major components of innate immunity, namely decreased neutrophil chemotaxis 
and phagocytosis thus impairing the ability of the host to combat  infection37,38. Second, it is possible that it is 
not the essence of diabetes itself, but the high sugar level close to surgery that increase susceptibility to surgical 
site infections. By reflecting glucose levels over the 2–3 weeks prior, fructosamine better reflects the glycemic 
control closer to surgery. Finally, fructosamine may be a more sensitive marker for glycemic disturbances in 
patients without  diabetes39.
This study had several limitations. First and most importantly, this was an observational study and while the 
results suggest an association between fructosamine and complications, we cannot say for sure that controlling 
fructosamine level would lead to a reduction in complication rates. Second, fructosamine was evaluated within 
1 month of surgery, and perhaps if it were taken closer to surgery, it may have been a better prognostic marker. 
Third, there are several factors that may affect serum protein levels, and therefore impact fructosamine levels, 
which we did not take into consideration. For example, hepatic cirrhosis, protein loosing enteropathies, and other 
conditions are known to affect plasma protein levels and possibly the level of fructosamine. Finally, fructosamine 
levels and the threshold used in this study may be affected by differences in labs and reagents used for testing. 
Future studies are needed to validate the threshold used in this study or suggest a more optimal cut-off level.
This multi-intuitional prospective study supports recent reports on the utility of fructosamine testing prior to 
total joint arthroplasty. Fructosamine holds major advantages over HbA1c in the preoperative period. We propose 
that centers without prior experience of using this test, consider adding the test to their screening programs for 
hyperglycemia, particularly in patients who have fasting glucose greater than 100 mg/dL.
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